Compounds and compositions for intracellular delivery of therapeutic agents
US-2018273467-A1 · Sep 27, 2018 · US
Oligomer-containing hydantoin compounds
US9540330B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9540330-B2 |
| Application number | US-201113994606-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2011 |
| Priority date | Dec 15, 2010 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a compound of formula: and pharmaceutically acceptable salts thereof, wherein: n is 1 to 12; and the compound is present in a dosage form. 2. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient. 3. The pharmaceutical composition of claim 1 , wherein n is 1 or 3-9.
Assignees
Inventors
Classifications
with hetero atoms or acyl radicals directly attached to ring nitrogen atoms · CPC title
- C07D233/72Primary
Two oxygen atoms, e.g. hydantoin · CPC title
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
Antiepileptics; Anticonvulsants · CPC title
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9540330B2 cover?
- The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
- Who is the assignee on this patent?
- Riggs-Sauthier Jennifer, Allums-Donald Stephanie, Nektar Therapeutics
- What technology area does this patent fall under?
- Primary CPC classification C07D233/72. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).